Navigation Links
VasoNova Inc. Announces Strategic Partnership With Navilyst Medical Inc.
Date:9/24/2010

MENLO PARK, Calif., Sept. 24 /PRNewswire/ -- VasoNova (VasoNova Inc., Menlo Park, California) announced a strategic partnership with Navilyst Medical Inc. (Navilyst Medical Inc., Marlborough, Massachusetts) today to distribute its VasoNova™ Vascular Positioning System™ VPS™ central venous catheter navigation technology.

Commenting on the partnership, Navilyst Senior Vice President, George Bourne said "Navilyst Medical is a market and technology leader in vascular access and fluid management with a long tradition of therapeutic innovation. Accurate catheter tip location is clinically beneficial to the patient and directly contributes to lowering healthcare costs. These two things are firmly aligned with our mission and reflected in our many other market leading innovations in vascular access. We are very excited to be bringing the VasoNova™ VPS™ catheter navigation technology to our customers. The combination of best-in-class central venous catheters from Navilyst and real time catheter tip positioning of this caliber from VasoNova provides the best possible solution to our clinicians and for our patients".    

Paul Molloy, President & Chief Executive Officer at VasoNova added, "VasoNova's VPS™ technology is the first real-time intra-vascular catheter navigation technology that does not require external metal detectors or viewing screens, nor subjective interpretation of ECG signals, and is capable of confirming precise catheter tip location using highly sophisticated anatomical location identification algorithms embedded in its technology. These location signatures are identified utilizing highly specific Doppler ultrasound characteristics combined with other patient data. The VasoNova™ VPS™ is compatible with all commonly used PICC and CVC catheters. Navilyst's world-class vascular access product offering is highly synergistic and together we offer clinicians unparalleled technological advantages".

VasoNova is a privately held company, founded in 2005 and has developed a completely unique central venous catheter navigation technology that allows real-time accurate confirmation of placement of PICC and CVC catheters in the lower one third of the superior vena cava, the optimal position for catheter tip location. More than ten million such catheters are placed in the United States each year.

Related link for more information: www.vasonova.com; www.navilyst.com


'/>"/>
SOURCE VasoNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... CITY , March 29, 2017  Bodycad ... and Drug Administration (FDA) 510(k) clearance for its ... of this truly personalized orthopaedic restoration. Bodycad is ... for a joint reconstruction implant system. ... to optimize personalized restoration of the patient,s unique ...
(Date:3/29/2017)... Global intravenous (IV) iron and oral iron market ... at a CAGR of 5%. Iron drugs ... treat anemia or other iron deficiencies. Oral iron supplements are ... in some cases, oral administrations are not capable of maintaining ... therapy comes into the picture. Global Intravenous (IV) ...
(Date:3/29/2017)... Research and Markets has announced the addition of the "Italy ... report to their offering. ... Proton Therapy Market in Italy will double by ... currently three proton therapy centers in Italy that ... Italy , the first patients were treated with proton beams in ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare partner ... with prominent executives from both inside and outside the cannabis industry. , Joining ... , who has more than twenty years of business leadership and investment experience in ...
(Date:3/29/2017)... ... 29, 2017 , ... HealthCareMandA.com will host an important webinar — Home Health ... ET. A recording of the webinar will also be made available following its live ... hospice companies are still popular targets for healthcare investors. This highly fragmented sector bounced ...
(Date:3/29/2017)... ... 29, 2017 , ... Immunotherapy has emerged as one of the most promising ... to be the next revolution in our fight against this complex disease. One of ... immune checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... have easier access to the robotic-assisted total-hip and partial-knee replacement surgeries that ... surgeons at Forbes Hospital and Jefferson Hospital recently started performing these surgeries ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of ... Julie Taffet Moelis, W’81, have made a $10 million gift to establish the ... that will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates whose ...
Breaking Medicine News(10 mins):